Open Actively Recruiting

First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer

About

Brief Summary

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-ADC in patients with advanced cancer

Primary Purpose
Treatment
Study Type
Interventional
Phase
Phase 1

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
18 Years
Maximum Age
N/A

Inclusion Criteria:

Exclusion Criteria:

Join this Trial

Share:
Study Stats
Protocol No.
22-000012
Category
Breast Cancer
Cervical Cancer
Colorectal Cancer
Esophageal Cancer
Kidney Cancer
Liver Cancer
Lung Cancer
Ovarian Cancer
Pancreatic Cancer
Sarcoma
Stomach Cancer
Contact
LISA-MARIA YONEMOTO
Location
  • TRIO-US - Ft. Wayne IN
  • TRIO-US - Fullerton
  • TRIO-US - Redondo Beach
  • UCLA San Luis Obispo
  • UCLA Santa Barbara
  • UCLA Santa Monica
For Providers
NCT No.
NCT05156866
For detailed technical eligibility, visit ClinicalTrials.gov.